Category: nature publishing group

Nature paper with massive correction can’t be reproduced, says independent group

In 2011, authors of a Nature letter caught some flak for issuing a lengthy correction to a neuroscience paper that had raised eyebrows within days of publication — including some suggestions it should be retracted.

The correction notice, published months after the original letter, cited errors in image choice and labeling, but asserted the conclusions remained valid.

Now, those conclusions appear up for debate. In a recent Nature Brief Communications Arising (BCA) article, a team that raised concerns about the paper five years ago says they are unable to reproduce the results. But the authors of the original paper aren’t convinced: They argue that the BCA fails to cite important evidence, has a “complete absence or low quality of analysis,” and the scientists disregard some of their data.

Continue reading Nature paper with massive correction can’t be reproduced, says independent group

Lack of reproducibility triggers retractions of Nature Materials articles

The authors of a highly cited 2015 paper in Nature Materials have retracted it, after being unable to reproduce some of the key findings.

The move prompted the journal to also retract an associated News & Views article.

Here’s the retraction notice for “Fast and long-range triplet exciton diffusion in metal–organic frameworks for photon upconversion at ultralow excitation power:” Continue reading Lack of reproducibility triggers retractions of Nature Materials articles

Karolinska requests retraction of 2014 Macchiarini paper

Paolo Macchiarini

It has been a tough couple of years for surgeon Paolo Macchiarini, once lauded for pioneering a groundbreaking procedure to transplant tracheas.

After a series of documentaries prompted his former employer, Karolinska Institutet (KI), to reopen a misconduct investigation against him, KI has today released one verdict regarding a 2014 Nature Communications paper: guilty.

KI said it is contacting the journal to request a retraction of the paper, which has already been flagged with an expression of concern.

Here’s more from a release from the institution: Continue reading Karolinska requests retraction of 2014 Macchiarini paper

Controversial gene-editing study flagged by Nature journal

nature-biotechnologyNature Biotechnology has issued an editorial expression of concern (EOC) for a widely criticized study describing a potentially invaluable new lab tool.

The EOC mentions the lack of reproducibility of the gene-editing technique, known as NgAgo. Alongside it, the journal has published a correspondence which includes data from three separate research groups that cast doubt on the original findings.

According to a spokesperson for the journal, some of the paper’s authors have objected to the decision to issue an EOC.

Earlier this month, we reported on a letter signed by 20 researchers which also raised concerns about the genome-editing activities of NgAgo — and alleged the lab that produced the initial results turned away investigators when they attempted to validate the tool in mammalian cells.

Here’s the EOC, published yesterday: Continue reading Controversial gene-editing study flagged by Nature journal

Nature Cell Biology retracts hotly debated cancer paper

ncbLast week, we learned a 2016 paper heavily discussed on PubPeer might be retracted — today, we learned that Nature Cell Biology has indeed pulled the paper, citing inappropriate image modifications.

As we reported last week, a comment on PubPeer flagged as coming from an author said they had requested a retraction. A representative of National Taiwan University (NTU) told us the first author had resigned, and the paper was under investigation — an investigation which included the last author, a prominent researcher who is also a vice president at another institution in Taiwan.

Here’s Nature Cell Biology‘s official statement about the paper, in the form of a retraction notice that appears to be written by the authors:  Continue reading Nature Cell Biology retracts hotly debated cancer paper

More questions arise over gene-editing tool

13238A new letter signed by 20 researchers is casting additional doubts on the validity of a potentially invaluable lab tool — and alleges the lab that produced the initial results turned them away when they tried to replicate its findings in mammalian cells.

In a letter published this week in Protein & Cell, the researchers add their voices to the critics of the gene-editing technique, first described earlier this year in Nature Biotechnology.

The researchers outline their attempts to apply the technique — known as NgAgo — to a variety of cell types, which fell short:

Continue reading More questions arise over gene-editing tool

Nature Cell Bio paper may be headed for retraction

ncbA Nature Cell Biology paper published only a few months ago by prominent researchers in Taiwan has sparked a heated discussion on PubPeer, which now includes a comment allegedly from an author saying they have requested its retraction.

Although a representative of the journal wouldn’t confirm to us that the authors had requested a retraction, the comment on PubPeer says the paper contains several figures that were “inappropriately manipulated” by the first author.

Here’s the full comment on PubPeer, tagged as coming from one of the authors of the paper:

Continue reading Nature Cell Bio paper may be headed for retraction

Macchiarini paper in Nature journal earns expression of concern for data questions

nature-communications-228x300Nature Communications has issued an expression of concern for a 2014 paper by beleaguered surgeon Paolo Macchiarini, citing concerns over whether the paper accurately reports the experiments that were carried out.

According to the notice, Macchiarini, a former rising star in the field of transplant medicine, agrees with the expression of concern. Three of his 22 co-authors have objected.

“Experimental orthotopic transplantation of a tissue-engineered oesophagus in rats” describes transplanting an esophagus into rats that was seeded with their own stem cells, and notes that all animals survived the study period (14 days), and gained more weight than rats given a placebo operation. It’s a topic Macchiarini has made famous, as the first surgeon to perform a similar procedure with a human tracheal transplant. But he’s faced charges of misconduct in the last few years, resulting in his dismissal from Karolinska Institutet (KI).

Here’s the text of the notice, scheduled to go live at 10 a.m. UK time today: Continue reading Macchiarini paper in Nature journal earns expression of concern for data questions

Cancer biologist says Nature journal “censored” his News & Views, retracts it

nature-reviews-clinical-oncologyA cancer biologist has retracted a 2016 News & Views article in a Nature journal, alleging that the journal tried to censor his writing by asking him to remove passages that criticized another journal (Cell). 

Carlo Croce, the sole author of the article in Nature Reviews Clinical Oncology from Ohio State University in Columbus, described the journal’s actions to us as “disgusting” and “worrisome.”

A spokesperson from the journal sent us this statement:

We regret that this situation occurred. We cannot comment beyond the retraction notice.

This isn’t Croce’s first retraction (we just found another recent one, in the Journal of Biological Chemistry, over image problems). He’s also co-authored multiple papers with Alfredo Fusco, a cancer researcher in Italy who has nine retractions under his belt, and is undergoing criminal investigation for scientific misconduct.

Here’s the retraction notice, published in Nature Reviews Clinical Oncology on October 4: Continue reading Cancer biologist says Nature journal “censored” his News & Views, retracts it

Second paper about major blood pressure drug trial in Japan to be retracted

hr_cimageA second paper about a major randomized trial in Japanese patients with heart disease is being retracted, after an investigation reportedly found multiple problems with the paper.

As predicted by Pharma Japan, Hypertension Research is retracting a 2011 paper, already the subject of two errata. Although a spokesperson said she couldn’t say why the paper was being retracted, as the notice was still in production, editor Toshihiko Ishimitsu told us: Continue reading Second paper about major blood pressure drug trial in Japan to be retracted